Chemiluminescence immunoassay and nucleic acid testing for TTI screening: A narrative review of performance, complementarity, and blood safety
Indonesian Journal of Blood And Transfusion · 09.11.2026 · 4 (2)
DOI: 10.51559/m7qq3j79 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indonesian Journal of Blood And Transfusion, online erschienen am 09.11.2026. Verfasst von Abdul Karim. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Screening for transfusion-transmitted infections (TTIs) is essential to blood safety. Chemiluminescence immunoassay (ChLIA) enables automated, high-throughput serological screening, whereas nucleic acid testing (NAT) detects viral nucleic acids and reduces the diagnostic window period. This review aimed to evaluate ChLIA for screening hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and syphilis; compare its performance with NAT for HBV, HCV, and HIV; and examine the implications for transfusion safety.
Methods
A directed narrative review was conducted by a single reviewer (A.K.). PubMed was searched on September 7, 2026, using a predefined, reproducible search strategy. Supplementary searches included peer-reviewed journals, reference lists, World Health Organization publications, and official Indonesian regulatory sources. Studies were prioritized according to their relevance to blood donor screening, ChLIA–NAT comparisons, residual transfusion risk, occult HBV infection, and Indonesian regulatory requirements. Uncertain records underwent full-text assessment.
Results
The included studies varied in assay characteristics, screening markers, donor populations, and reference standards, precluding meaningful pooling or generalization of diagnostic accuracy estimates. ChLIA and NAT detect distinct biological targets, with their relative contributions to blood safety influenced by pathogen epidemiology, residual risk, regulatory requirements, and healthcare resources. Findings from Shahin et al. and the Indonesian study are presented with their respective denominators and discordant testing patterns to ensure appropriate interpretation.
Conclusion
ChLIA demonstrates high diagnostic performance, although accuracy varies across assays and clinical settings. Its complementary use with NAT may enhance transfusion safety when guided by pathogen-specific residual risk, local epidemiology, regulatory requirements, and healthcare capacity. Both approaches should be integrated within comprehensive quality assurance and hemovigilance systems.
Zitieren
APA
Karim, A. (2026). Chemiluminescence immunoassay and nucleic acid testing for TTI screening: A narrative review of performance, complementarity, and blood safety. Indonesian Journal of Blood And Transfusion, 4(2). https://doi.org/10.51559/m7qq3j79
Vancouver
Karim A. Chemiluminescence immunoassay and nucleic acid testing for TTI screening: A narrative review of performance, complementarity, and blood safety. Indonesian Journal of Blood And Transfusion. 2026;4(2). doi:10.51559/m7qq3j79
BibTeX
@article{Karim2026,
author = {Karim, Abdul},
title = {Chemiluminescence immunoassay and nucleic acid testing for TTI screening: A narrative review of performance, complementarity, and blood safety},
journal = {Indonesian Journal of Blood And Transfusion},
year = {2026},
volume = {4},
number = {2},
doi = {10.51559/m7qq3j79}
}
EUVIMED